Published in AIDS Weekly, September 29th, 2003
AMD070 targets the CXCR4 chemokine receptor and prevents HIV from entering and infecting healthy cells. CXCR4 and CCR5 inhibitors belong to the new investigational class of antiretroviral drugs known as HIV entry inhibitors.
"Recent clinical results indicate that CXCR4 using strains of HIV affect approximately 40% of patients and that these strains are more damaging to the immune system than CCR5 using strains. Given the increasing amount of evidence we believe CXCR4 inhibitors have an important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.